Radiographic progression-free survival as a clinically meaningful end point in metastatic castration-resistant prostate cancer: the PREVAIL randomized clinical trial
Importance Drug development for metastatic castration-resistant prostate cancer has been
limited by a lack of clinically relevant trial end points short of overall survival (OS).
Radiographic progression-free survival (rPFS) as defined by the Prostate Cancer Clinical
Trials Working Group 2 (PCWG2) is a candidate end point that represents a clinically
meaningful benefit to patients. Objective To demonstrate the robustness of the PCWG2
definition and to examine the relationship between rPFS and OS. Design, Setting, and …
limited by a lack of clinically relevant trial end points short of overall survival (OS).
Radiographic progression-free survival (rPFS) as defined by the Prostate Cancer Clinical
Trials Working Group 2 (PCWG2) is a candidate end point that represents a clinically
meaningful benefit to patients. Objective To demonstrate the robustness of the PCWG2
definition and to examine the relationship between rPFS and OS. Design, Setting, and …
以上显示的是最相近的搜索结果。 查看全部搜索结果